Quality of Life and Depression in Dialysis Patients (QOLD)

Fresenius Medical Care (FMC)

Status: Completed

Conditions: Chronic Kidney Disease Stage 5

Study type: Observational

Funder types: Industry

Identifiers

NCT01668628

QOLD_01_052012

Details and patient eligibility

About

The aim of this study is to evaluate quality of life (QOL) and depression in peritoneal dialysis patients compare to hemodialysis patients and assess hydration effect on QOL and depression over time.

Full description

In dialysis patients, low QOL and depression affects clinical outcomes such as morbidity and mortality.

Therefore at the point of treating dialysis patients, It is important to provide not only physical health but also psychosocial health.

QOL could be decided by physical health (i.e. sign and symptom, laboratory results, death) and psychological health (i.e. fatigue, pain, consciousness of health and satisfaction).

And also generally it is well known that physical and psychological functions in dialysis patients are decreased.

And especially depression is common disease in dialysis patients. It is also well known that about from 25 to 50 percent of dialysis patients have depression which could result in low QOL moreover hospitalization, complication, and mortality.

But there is no QOL and depression study with hydration status. Therefore the investigators would like to explore it.

The objective of the study is to evaluate quality of life (QOL) and depression in dialysis patients and assess the hydration effect on QOL and depression over time

Enrollment: 1,068 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Dialysis patients, age from 18 years to 75 years
• Incident continuous ambulatory peritoneal dialysis(CAPD) or automated peritoneal dialysis(APD) patients who don't have any experience of dialysis treatment before this study
• Prevalent peritoneal dialysis(PD) patients who are getting peritoneal dialysis treatment more than 6 months
• Prevalent hemodialysis (HD) patients who are getting haemodialysis treatment more than 6 months
• The subjects who are eligible for 1 year follow up
• Written informed consent before any trial related activities
• Eligible patients to complete questionnaire

Exclusion criteria

• Prognosis for survival less than 3 months

• Kidney transplantation less than 15 months

• Ineligible patients for questionnaire

• Any malignancies and ascites

• Any condition which could interfere with the patient's ability to comply with the study protocol

• Ineligible to measure BCM

  1. pacemaker, defibrillator
  2. pregnancy or lactation period
  3. amputation
  4. artificial joint

Trial design

1,068 participants in 3 patient groups

Incident PD patients

Description:

First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study

Prevalent PD patients

Description:

Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months

Prevalent HD patients

Description:

Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months